PCM
NEPH icon

Prelude Capital Management’s Nephros NEPH Stock Holding History

Prelude Capital Management’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,680
Closed -$40.8K – 1430
2026
Q1 		$40.8K Sell
13,680
-1,500
-10% -$5.99K ﹤0.01% 1138
2025
Q4 		$74.1K Buy
+15,180
New +$77.6K 0.01% 1216
2020
Q2 		– Sell
-367
Closed -$2K – 2162
2020
Q1 		$2K Hold
367
– – ﹤0.01% 1314
2019
Q4 		$4K Buy
+367
New +$3.27K ﹤0.01% 1789

Other funds holding NEPH

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Prelude Capital Management's NEPH Position: Q2 2026 in Review

Prelude Capital Management sold out of Nephros (NEPH) in Q2 2026, closing a stake of 13,680 shares — an estimated $40.8K sold.

Prelude Capital Management first reported a position in NEPH in Q4 2019 and held it in 4 quarters. The position peaked at $74.1K in Q4 2025. 33 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • Prelude Capital Management reported no remaining Nephros position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 13,680 Nephros shares in Q2 2026, an estimated $40.8K.
  • Prelude Capital Management first reported a position in Nephros in Q4 2019 and held it in 4 quarters.
  • Prelude Capital Management's Nephros position peaked at $74.1K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.